Work

Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-146348

Authors: Alexey V. Danilov, Vi Lam, Bria Thurlow, Stephen E. Spurgeon, Byung Park, Kirsten Orand, Adam S Kittai

Institutions: City Of Hope National Medical Center, City of Hope, Oregon Health & Science University, The Ohio State University

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3215536407

Cites:

Cited by: 3

Related to: 10